Building the next generation of non-invasive cardiac monitoring
The problem
Heart failure represents one of the largest and fastest-growing challenges in global healthcare and placing increasing pressure on healthcare systems.
There is a clear unmet need for monitoring approaches that are scalable, patient-friendly, and compatible with long-term use.
The opportunity
Heart failure affects more than 60 million people worldwide and remains one of the leading causes of hospitalization and death, growing by over 10% every year.
TAM > $25B
The solution
KardioVis is developing a non-invasive cardiac monitoring platform that combines rapid signal acquisition with advanced data analysis.
The technology is designed to integrate into existing care pathways and support structured clinical evaluation over time.
Development status
Second-generation prototype completed:
Early validation activities conducted across home and clinical environments
Structured clinical validation program planned in collaboration with academic cardiology centers
Regulatory pathway aligned with MDR and FDA requirements
Founding rounds
KardioVis is raising a seed funding round to support the next phase of development.
Use of proceeds will focus on:
Product industrialization
CE mark for MDR Class IIa and product lunch
Planning of multi-centric international clinical study
Team expansion in engineering and clinical operations
The plan
Key milestones (next 12–18 months)
Completion of industrialized product
Initiation of first clinical validation study (authorized, enrollment starting in September 2026)
Preparation of MDR technical documentation
Expansion of clinical and strategic partnerships